Acirax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acirax

What is Acirax?

Acirax is an antiviral medication specifically designed to treat infections caused by certain types of viruses. It belongs to a class of drugs known as synthetic purine nucleoside analogues. The primary goal of this medication is to interfere with the way specific viruses replicate within the human body.

Mechanism of Action

The active therapeutic process of Acirax involves the inhibition of viral DNA synthesis. When the medication enters a cell infected by a virus, it undergoes a chemical conversion that allows it to compete with the natural building blocks of viral DNA. By incorporating itself into the developing DNA chain of the virus, it acts as a termination agent, preventing the virus from completing its genetic replication.

Because the medication requires specific viral enzymes to become fully active, its primary effect is concentrated within infected cells, leaving healthy, non-infected cells largely unaffected by the DNA-disruption process.

Therapeutic Applications

Acirax is utilized in the management of several conditions resulting from the herpes simplex virus (HSV) and the varicella-zoster virus (VZV). These include:

  • Herpes Simplex: Management of skin and mucous membrane infections, including initial and recurrent episodes of genital herpes.
  • Herpes Zoster: Treatment of shingles, a condition caused by the reactivation of the varicella-zoster virus.
  • Varicella: Management of chickenpox infections.

While Acirax is effective at reducing the severity and duration of these viral outbreaks, it is important to note that it is not a cure for these infections. The viruses that cause these conditions typically persist in the body in a latent state even after the symptoms of an active outbreak have been treated.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Acirax?

Possible Side Effects and Safety Information

The official safety profile for Aciclovir (Acirax) is structured by classifying possible adverse reactions according to their frequency and the body system affected, based on regulatory standards.

Frequency-Classified Adverse Reactions

Adverse events are categorized by regulatory documents as follows:

  • Common (ge 1/100 to <1/10): Reactions frequently observed include headache, dizziness, nausea, vomiting, diarrhoea, and rashes (including photosensitivity).
  • Uncommon (ge 1/1,000 to <1/100): Examples include urticaria and accelerated diffuse hair loss.
  • Very Rare (<1/10,000): These include serious reactions like acute renal failure, hepatitis, jaundice, and severe neurological effects such as encephalopathy, convulsions, or coma.

System-Organ-Class Groupings

Regulatory sources group reported effects into classes such as Gastrointestinal disorders, Psychiatric and nervous system disorders, Skin and subcutaneous tissue disorders, Renal and urinary disorders, and Blood and lymphatic system disorders.


Safety Considerations for Specific Populations

Official labeling contains specific notes for certain patient groups. Elderly patients and individuals with renal impairment are documented as having an increased risk of neurological side effects (e.g., confusion, agitation), which are typically noted as reversible upon discontinuation of treatment. For patients receiving high oral doses, maintaining adequate hydration is a documented safety constraint to help prevent renal issues. The risk of renal impairment is officially noted to be increased when Acirax is used concomitantly with other nephrotoxic agents.

This information represents the official, label-derived safety data for Aciclovir and should not be interpreted as medical advice.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Acirax

This section outlines the officially documented clinical profile and required actions in the event of Acirax overdosage, as defined by authoritative governmental regulatory documents.

Documented Overdose Presentations

Signs and symptoms of overdosage reported in regulatory sources include severe nausea and vomiting, dizziness, fine motor tremors, ataxia, and nystagmus. In profound cases, patients may exhibit a depressed level of consciousness progressing to lethargy or coma. Overdosage carries a documented risk to multiple body systems, including the Central Nervous System, the Renal System, and the Cardiovascular System.

Critical Outcomes and Immediate Actions

Severe Acirax overexposure is associated with the potential for acute renal failure due to metabolite accumulation, generalized tonic-clonic seizures, and cardiac arrhythmia, specifically QTc prolongation.

Urgent medical attention must be sought immediately following suspected or confirmed overdosage, regardless of the patient’s initial symptomatic state. Contact emergency medical services or a poison control center right away.

Management and Monitoring

There is no known specific antidote for Acirax overdose. Management is supportive and symptomatic. Regulatory instructions mandate attention to adequate hydration to mitigate renal risk and continuous patient observation, including serial monitoring of renal function and continuous ECG monitoring.

Special attention is required for pediatric patients (who may show CNS excitation) and individuals with pre-existing renal impairment due to increased risk of systemic accumulation and damage.

Therapeutic Uses of Acirax

Quick Facts: Uses of Acirax

  • Genital Herpes: Helps manage initial and recurrent outbreaks.
  • Cold Sores (Herpes Labialis): May assist in healing and symptom management.
  • Shingles (Herpes Zoster): Used to treat infections caused by this virus.
  • Chickenpox (Varicella): Indicated for use in managing this condition.

Acirax is a prescription medication utilized in the management of infections caused by certain herpes viruses. The primary therapeutic domain of Acirax is to help manage the symptoms associated with these viral conditions, including outbreaks of genital herpes and the manifestation of cold sores.

The medication is also indicated for use in managing infections caused by the varicella-zoster virus, which includes both chickenpox (varicella) and shingles (herpes zoster). While the drug may help relieve discomfort and promote the healing of sores, it does not cure the underlying viral infection. Its use is focused on minimizing the severity and duration of the viral episode.

Patients should rely on a healthcare professional’s guidance regarding the appropriate use of this medication.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Acirax?

This section outlines the official population eligibility rules for Acirax (Aciclovir), as defined by governmental regulatory authorities.


Eligibility Scope

Category Regulatory Status
Absolute Contraindication Contraindicated in patients with known hypersensitivity to the active ingredient, Aciclovir, or the related drug, Valaciclovir.
Approved Age Groups Adults and Adolescents (12+) are approved for standard use. Children (2+) are approved for specific indications like chickenpox.
Pediatric Restriction Use in infants under two years old is generally not established for standard indications and is reserved for specialized protocols.
Organ Function Status Eligibility for patients with renal impairment is conditional and requires cautious management. The need for dosage adjustment must be considered, as the drug is cleared through the kidneys.
Geriatric Caution Older adults require special consideration and caution due to the higher likelihood of reduced renal function.
Pregnancy and Lactation Use during pregnancy and breastfeeding is generally not recommended unless the potential therapeutic benefit outweighs the risk, as per official labeling.

Regulatory Basis

The official eligibility criteria are primarily defined by the absolute prohibition against use due to hypersensitivity and various restrictions based on age and organ function. Use in populations such as the elderly, pregnant individuals, and those with kidney impairment is formally restricted or requires increased caution to manage the specific risks noted in government prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acirax is eliminated primarily by the kidneys, largely unchanged, which dictates the types of drug interactions that are clinically significant and officially documented in regulatory information.

Pharmacokinetic Interactions

The most important documented interactions involve medicines that reduce the renal clearance of Acirax. Co-administration of Acirax with Probenecid results in a significant increase in the mean plasma half-life and systemic exposure (AUC) of Acirax. This effect occurs because Probenecid inhibits the active renal tubular secretion of Acirax. Similarly, Cimetidine has been documented to cause a modest increase in Acirax's exposure by reducing its renal clearance.

Pharmacodynamic Interactions

There is an increased potential for additive organ toxicity when Acirax is co-administered with other medicines that are also known to be nephrotoxic (toxic to the kidneys). This combination requires caution, particularly in patients with pre-existing renal impairment. Furthermore, when Acirax is administered concurrently with Mycophenolate Mofetil (an immunosuppressant), there is a documented potential for increased plasma concentrations of both the inactive metabolite of Mycophenolate Mofetil and Acirax due to competition for renal elimination pathways.

Food and Timing

Acirax may be administered with or without food, as meals do not significantly affect its absorption or bioavailability. No specific dose-spacing requirements are typically mandated in the regulatory label for most co-administered medications.

Mechanism of Action

Selective Activation by Viral Enzymes

Acirax operates as a nucleoside analog and relies on a highly specialized mechanism to achieve its antiviral action. The drug is activated almost exclusively by the Viral Thymidine Kinase (TK) enzyme, which is unique to virus-infected cells. This crucial initial step of selective bioactivation leads to the concentration of the drug's active form precisely where the virus is replicating, leaving functional activity in non-infected cells largely unchanged and serving as the basis for its selective physiological activity.


Inhibition of Viral DNA Synthesis

Once activated into its triphosphate form, the drug acts as a decoy molecule to inhibit the Viral DNA Polymerase, the enzyme responsible for copying the virus's genetic material. The drug is incorporated into the growing viral DNA strand, but because it lacks the necessary chemical group, it immediately causes obligate DNA chain termination. This key molecular event prevents the production of new viral genomes. This combined action limits the capacity of the virus to replicate and be assembled for subsequent cellular dissemination, thereby maintaining function in non-infected tissues.

Dosage and Administration Information

How Acirax is Used: Official Administration Guidelines

The usage of Acirax (aciclovir) is defined by instructions regarding the route, dosage, frequency, and patient-specific conditions. Treatment should be initiated as early as possible following the first signs or symptoms of an outbreak to adhere to efficacy principles.


Official Administration Scope

Parameter Instruction
Route of Administration Oral ingestion (tablet, suspension), Intravenous (IV) infusion, Topical (cream, ophthalmic ointment), and Buccal tablet.
Dosing Schedule & Frequency Oral doses range from 200 mg to 800 mg per dose. Acute treatment regimens typically require dosing four to five times daily for a fixed course (e.g., 5 to 10 days). Suppressive therapy is commonly 400 mg twice daily.
Timing in Relation to Meals Oral formulations may be taken with or without food.

Procedural and Adjustment Requirements

Special Conditions and Preparation

  • Hydration: Patients must maintain adequate hydration during oral and IV therapy to support renal function.
  • IV Use: Intravenous administration must be performed as a slow infusion over at least one hour and is forbidden via rapid/bolus injection or intramuscular/subcutaneous routes.
  • Topical Use: Cream should be applied externally and must not be used on mucous membranes (e.g., in the eye or mouth).

Population Adjustments

  • Renal Impairment: Dose reduction is formally required in patients with reduced renal clearance to prevent drug accumulation.
  • Older Adults: Dose consideration is necessary due to the likelihood of age-related decline in kidney function.

If a dose is missed, it should be taken as soon as remembered; however, if it is almost time for the subsequent dose, the missed dose is to be skipped to avoid a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acirax


Evidence for Use in Genital Herpes and Suppressive Therapy

Research exploring Acirax for genital herpes has accumulated a large body of evidence, relying heavily on short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, and they typically included immunocompetent adults experiencing both initial and repeat episodes. Researchers focused on outcomes related to physical discomfort, such as measuring the time required for lesions to heal and crust over, and tracking viral shedding rates.

Studies monitored outcomes reflecting daily functioning and reporting observations about the duration and severity of pain and local symptoms throughout the acute phase. Research has explored separate, longer-duration studies focusing on suppressive therapy. These studies monitored the frequency of recurrence in patients receiving continuous observation for up to a year. What is known about the long-term functional outcomes and disease progression beyond one year of continuous therapy is not as comprehensively characterized in standardized research.


Evidence for Use in Shingles (Herpes Zoster)

The evidence structure for shingles (Herpes Zoster) is built upon trials that primarily consisted of acute-phase Randomized Controlled Trials (RCTs). Study outcomes focused on the timing of lesion crusting and full resolution, and the duration of acute zoster-associated pain. A key outcome studies monitored was the surveillance for the development and persistence of postherpetic neuralgia (PHN)—a potentially long-lasting pain condition. The main study populations were immunocompetent adults, with specific attention given to older adult cohorts.

Trial reports described observations concerning the rate of lesion healing across study groups in the typical seven- to twenty-one-day window. Data were reported on the measured duration of acute pain, noting patterns of resolution compared to controls. The available research provides limited comparative data on the ultimate resolution of PHN when comparing Acirax to all other available antiviral treatments.


What Is Still Uncertain About Acirax Research

Although Acirax was studied for several indications, research is ongoing in several key areas. Follow-up durations were limited in many acute studies, and long-term effects are not fully established for controlling disease progression over decades. Comparative evidence is lacking against all the newer generation antiviral medicines for all approved indications. Also, data for certain groups, such as those with specific severe comorbidities or those who may experience viral resistance, remain insufficient to draw broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Acirax (FAQ)


Q: Is Acirax the same as [Name of similar common drug]?

Aciclovir is the active ingredient contained within Acirax and is classified as a synthetic nucleoside analog. Official documents indicate that Aciclovir is the established generic name for the drug, which is also distributed under several brand names globally, though the core chemical compound remains the same.


Q: Can Acirax be taken long-term?

Studies have explored the use of Aciclovir for suppressive therapy, which may last up to 12 months. However, the official research evidence regarding long-term functional outcomes beyond one year of continuous therapy is not as comprehensively established. Decisions regarding the appropriate duration of therapy are generally made by a healthcare provider.


Q: Can Acirax affect my sleep?

Official safety profiles note the potential for effects on the central nervous system (CNS). These documented effects include reports of dizziness and, in rare instances, sleepiness or confusion. Regulatory information indicates that older adults may require special consideration regarding these CNS effects.


Q: What is the safety profile of Acirax during pregnancy?

Aciclovir is categorized as FDA Pregnancy Category B. Data collected from a prospective registry found that the occurrence rate of birth defects in women exposed during the first trimester approximated that of the general population. Use during pregnancy is generally not recommended unless the potential therapeutic benefit outweighs the potential risk, as per official labeling.


Q: Is Acirax a generic drug or a brand name?

The official documentation indicates that Aciclovir is the established generic name for the active ingredient. The product name 'Acirax' is a brand name containing this active ingredient. Many countries utilize the generic name, Aciclovir, for this medicine.


Q: What happens if I miss a dose of Acirax?

Regulatory guidance instructs that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the subsequent dose, the missed dose should be skipped entirely to avoid taking a double dose.


Q: What should I do if I think I took too much Acirax?

Overdose can result in symptoms such as agitation, seizures, or decreased urination, and these may be serious. Official guidance indicates that if an overdose is suspected, contacting emergency medical services or a poison control center is advised.


Q: Does Acirax require any specific monitoring (like blood tests)?

Official patient information indicates that the need to monitor for signs of renal impairment (kidney issues) is noted, particularly in patients with pre-existing kidney issues or those receiving high doses. Official safety information notes the importance of maintaining adequate hydration during treatment.


Q: Can I drive or operate machinery while on Acirax?

Official prescribing information notes that due to the potential for adverse effects on the nervous system, such as dizziness, headache, or confusion, the operation of vehicles or machinery should be considered with care.


Q: Does Acirax cause any mood changes?

The official safety profile includes central nervous system (CNS) disorders. Rare but severe neurological effects such as confusion, hallucinations, and, in isolated cases, agitation, have been documented in official regulatory sources.


Q: What is the half-life of Acirax?

According to the official prescribing information, the mean plasma elimination half-life for Aciclovir in adults with normal kidney function is documented to be between 2.5 to 3.3 hours. The half-life describes the time it takes for half of the drug to be eliminated from the bloodstream.


Q: Is Acirax approved in countries other than the US/UK?

The active ingredient, Aciclovir, is listed on the World Health Organization (WHO) Model List of Essential Medicines. This international status signifies its recognized efficacy and importance in global healthcare systems, supporting its widespread use.


Q: What are the common signs of an allergic reaction to Acirax?

Official safety information advises seeking immediate medical attention for signs of a severe allergic reaction, which may include difficulty breathing, swelling of the face or tongue, hives, or rash. Rashes and urticaria (hives) are noted in the frequency-classified adverse reactions section.


Q: How quickly does Acirax start working?

Pharmacokinetic studies indicate that peak blood concentrations of the drug typically occur between 1.5 to 2.5 hours following oral administration. Official documents indicate that for certain conditions, the initiation of treatment within 48 hours of symptom onset is noted in efficacy studies.


Q: Does Acirax stay in your system for a long time?

Official documents indicate the active ingredient has a mean plasma elimination half-life of 2.5 to 3.3 hours in adults with normal kidney function. This value describes the rate at which the drug is cleared from the bloodstream, as the drug is primarily eliminated by the kidneys.


Q: Is it normal to feel [General common side effect] when starting Acirax?

Official documents note that common adverse reactions, such as headache, nausea, and diarrhoea, are frequently observed during the course of treatment. These are reported in a defined percentage of patients (ge 1/100 to <1/10) based on regulatory safety profiles.


Q: Can Acirax be used by teenagers or children?

Aciclovir is approved for use in adults and adolescents aged 12 years and older for standard indications. Furthermore, official labeling indicates that it is also approved for use in children aged 2 years and older for specific indications, such as chickenpox.

How should Acirax be stored and disposed of?

Storage & Disposal of Acirax (Oral Forms)

Storage Requirements:

  • Temperature: Store the medication at controlled room temperature, typically between 59mathrmF to 77mathrmF (15mathrmC to 25mathrmC).
  • Protection: Keep the container tightly closed and protect it from both moisture and light.
  • Handling: Do not store this medicine in a bathroom. Keep it in the container that it came in.
  • Children: Keep Acirax and all medicines out of the sight and reach of children.

Disposal Requirements:

  • Expired/Unused: Dispose of any unused or expired medication by following official safe disposal guidelines.
  • Methods: The preferred method is to drop off the medicine at a drug take-back location or use a mail-back program where available.
  • Household Trash: If a take-back option is not available, most medicines can be thrown in the household trash. First, mix the medicine with an undesirable substance (like dirt or used coffee grounds) and place the mixture in a sealed plastic bag before discarding it. Do not crush tablets or capsules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acirax found in:

A-Z Index: